Additive effects of IL-2 and protein kinase a type I antagonist on function of T cells from HIV-infected patients on HAART

AIDS

Volumn 13, Issue 17, 1999, Pages

  Aandahl, Einar Martin ^a   Aukrust, Pål ^a   Müller, Fredrik ^a   Hansson, Vidar ^a   Taskén, Kjetil ^a,b   Frøland, Stig S ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b Sect Clin Immunol Infect Dis   (Norway)

Author keywords

AIDS; Cyclic AMP; HIV; Interleukin 2; Protein kinase A

Indexed keywords

ANTIRETROVIRUS AGENT; CD3 ANTIGEN; CYCLIC AMP DEPENDENT PROTEIN KINASE; DIDANOSINE; INDINAVIR; INTERLEUKIN 2; NELFINAVIR; NUCLEOSIDE ANALOG; PROTEIN KINASE INHIBITOR; PROTEINASE INHIBITOR; RP 8 BR CAMPS; STAVUDINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; IMMUNOTHERAPY; LYMPHOCYTE PROLIFERATION; MALE; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0032762607     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199912030-00001     Document Type: Article

References (25)

1. Kammer CM. The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response. Immunol Today 1988, 9:222-229.
2. Skålhegg BS, Landmark BF, Døskeland SO, Hansson V, Lea T, Jahnsen T. Cyclic AMP-dependenl protein kinase type I mediates the inhibitory effect of 3′,5′-cyclic adenosine monophosphate on cell replication in human T lymphocytes. 1 Biol Chem 1992,267:15707-15714.
3. Skålhegg BS, Taskén K, Hansson V, Huitfeldt HS, Jahnsen T, Lea T. Location of cAMP-dependent protein kinase type I with the TCR/CD3 complex. Science 1994, 263:84-87.
4. Aandahl EM, Aukrust P, Skålhegg BS, et al. Protein kinase type I antagonist restores immune responses of T-cells from HIV-infected patients. FASEB J 1998, 12:855-862.
5. Deeks SG, Smith M, Holodnyi M, Kahn JO. HIV-1 protease inhibitors. JAMA 1997, 277:145-153.
6. Hammer SC, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4+ cell counts of 200 per cubic millimeter or less. N Engl j Med 1997, 337:725-733.
7. Gulick RM. HIV treatment strategies. JAMA 1998, 279:957-959.
8. Vandamme AM, Van Laethem K, De Clercq E. Managing resistance to anti-HIV drugs: an important consideration for effective disease management. Drugs 1999, 57:337-361.
9. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-F58.
10. Pantaleo C. How immune-based intervention can change HIV therapy. Nature Med 1997, 3:483-486.
11. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997, 94:13193-13197.
12. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nature Med 1999, 5:512-517.
13. Chun T-W, Engel D, Mizell SB, et al. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nature Med 1999, 5:651-655.
14. Hengge UR, Coos M, Esser S, et al. Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients. AIDS 1998, 3:F225-F234.
15. Aukrust P, Froland SS, Müller F. Raised serum neopterin levels in patients with primary hypogammaglobulinaemia; correlation to other immunological parameters and to clinical and histological features. Clin Exp Immunol 1992, 89:211-216.
16. Waldmann TA. The interleukin-2 receptor, y Biol Chem 1991, 266:2681-2684.
17. Anastassiou ED, Paliogianni F, BaloW JP, Yamada H, Boumpas DT. Prostaglandin E2 and other cyclic AMP-elevating agents modulate IL-2 and IL-2Ra gene expression at multiple levels. 1 Immunol 1992, 148:2845-2852.
18. Chouaib S, Weite K, Mertelsman R, Dupont B. Prostaglandin E2 acts at two distinct pathways of T lymphocyte activation:inhibition of interleukin 2 production and down-regulation of transferrin receptor expression. J Immunol 1985, 135:1172-1179.
19. Kolenko V, Rayman P, Roy B, et al. Downregulation of JAK3 protein levels in T lymphocytes by prostaglandin E2 and other cyclic adenosine monophosphate-elevating agents:impact on interleukin-2 receptor signaling pathway. Blood 1999, 93:2308-2318.
20. Davey RT jr, Chaitt DC, Albert JM, et al. A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. J Infect Dis 1999, 179:849-858.
21. Berthiaume Y, Boiteau P, Pick G, et al. Pulmonary edema during IL-2 therapy: combined effect of increased permeability and hydrostatic pressure. Am J Respir Crit Care Med 1995, 152:329-335.
22. Levy Y, Capitant C, Carriere I, et al. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomized controlled trial, lancet 1999, 353:1923-1929.
23. Thomas CA, Weinberger OK, Ziegler BL, et al. Human immunodeficiency virus-1 env impairs Fcg receptor-mediated phagocytosis via a cyclic adenosine monophosphate-dependent mechanism. Blood 1997, 90:3760-3765.
24. Haraguchi S, Good RA, Day NK. Immunosuppressive retroviral peptides: cAMP and cytokine patterns. Immunol Today 1995, 16:595-603.
25. Cole SW, Jamieson BD, Zack JA. cAMP up-regulates cell surface expression of lymphocyte CXCR4; implications for chemotaxis and HIV-1 infection. J Immunol 1999, 162:1392-1400.